{"success":true,"data":{"pressRelease":{"id":"133934","rtpr_id":"nBwbpJx2Ga","ticker":"NAGE","exchange":"NASDAQ","all_tickers":["NAGE"],"title":"Niagen Bioscience to Present at Longevity Investors Conference","author":"Business Wire","published_at":"2026-09-02T12:32:00.145Z","article_body":"Niagen Bioscience to Present at Longevity Investors Conference\n\nNiagen Bioscience, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.niagenbioscience.com%2F&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=Niagen+Bioscience%2C+Inc.&index=1&md5=54ac3dcc4677860f8c64935d818624f4)\n(NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine\ndinucleotide) with a focus on the science of healthy aging, today announces\nthat senior management will participate at the Longevity Investors Conference\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.longevityinvestors.ch%2F&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=Longevity+Investors+Conference&index=2&md5=29d560d7f29c38f3b5547b4ea27ed6ce)\n, taking place from September 14 to 17, 2026, in Gstaad, Switzerland.\n\nNiagen Bioscience CEO, Rob Fried, will participate in the Longevity Goes\nMainstream: The Investment Case for Consumer Health Panel on Wednesday,\nSeptember 16, from 14:50 - 15:30 p.m. CEST. Additionally, Mr. Fried and Niagen\nBioscience Chief Financial Officer & Head of Business Development, Ozan\nPamir, will attend one-on-one meetings with investors in person throughout the\nconference. Attendees will also have the opportunity to sample Tru Niagen(®)\non-site and experience Niagen™ Plus.\n\nThis year’s event will feature institutional investors, family offices,\nfunds, and private investors with the world’s leading longevity scientists\nand key opinion leaders hosting panel discussions to create a forum aimed at\namplifying breakthrough research and scientific advancement shaping the future\nof the longevity space.\n\nIf you would like to schedule a one-on-one meeting with the Niagen Bioscience\nmanagement team during the conference, please contact your respective\nconference representative or email Niagen@KCSA.com (mailto:Niagen@KCSA.com) .\n\nFor additional information on Niagen Bioscience, visit\nwww.niagenbioscience.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.niagenbioscience.com&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=www.niagenbioscience.com&index=3&md5=2d9fcdedf7744202de96e47fd71b0990)\n.\n\nAbout Niagen Bioscience\n\nNiagen Bioscience, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.niagenbioscience.com%2F&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=Niagen+Bioscience%2C+Inc.&index=4&md5=91ef63b35ff133358237c4d430c03bee)\n(NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide\nadenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries,\nNiagen Bioscience(™) is dedicated to advancing healthspan through precision\nscience and innovative NAD+-boosting solutions.\n\nThe Niagen Bioscience team, composed of world-renowned scientists, works with\nindependent investigators from esteemed universities and research institutions\naround the globe to uncover the full potential of NAD+. A vital coenzyme found\nin every cell of the human body, NAD+ declines with age and exposure to\neveryday lifestyle stressors. NAD+ depletion is a key contributor to\nage-related changes in health and vitality.\n\nDistinguished by state-of-the-art laboratories, rigorous scientific and\nquality protocols, and collaborations with leading research institutions\nworldwide, Niagen Bioscience sets the gold standard for research, quality, and\ninnovation. There’s a better way to age.\n\nAt the heart of its clinically tested product portfolio is Niagen(®)\n(patented nicotinamide riboside, or NR), the most efficient, well-researched,\nand high-quality NAD+ booster available. Niagen powers the Company’s\nconsumer supplement, Tru Niagen(®), the number one NAD+ boosting oral\nsupplement in the United States† (available at www.truniagen.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.truniagen.com&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=www.truniagen.com&index=5&md5=a45b8074c93bb2c21c8f7c72385abf48)\n), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and\ninjectable Niagen products (www.niagenplus.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.niagenplus.com&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=www.niagenplus.com&index=6&md5=346991c9ebe4026ac930635a078e26b0)\n). Pharmaceutical-grade Niagen IV and injections are compounded and\ndistributed by U.S. FDA-registered 503B outsourcing facilities and are\navailable exclusively at clinics with a prescription. NAD Pharmaceuticals\nCorp., the Company’s wholly owned subsidiary focused on developing therapies\nfor accelerated aging and rare genetic diseases, is conducting research on\nNB4168, a differentiated small molecule.\n\nNiagen Bioscience’s robust patent portfolio protects NR and other NAD+\nprecursors. Niagen Bioscience maintains a website at www.niagenbioscience.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.niagenbioscience.com&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=www.niagenbioscience.com&index=7&md5=58cf5409997dfc1b23998164161facde)\n, where copies of press releases, news, and financial information are\nregularly published.\n\n(†)Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 –\nDec. 2025)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260902223169/en/\n(https://www.businesswire.com/news/home/20260902223169/en/)\n\nNiagen Bioscience Media Contact:\nKendall Knysch, Senior Director of Media Relations & Partnerships\n310.405.5227\nkendall.knysch@niagenbio.com (mailto:kendall.knysch@niagenbio.com)\n\nNiagen Bioscience Investor Relations Contact:\nValter Pinto, Managing Director\nKCSA Strategic Communications\n212.896.1254\nNiagen@kcsa.com (mailto:Niagen@kcsa.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwbpJx2Ga","title":"Niagen Bioscience to Present at Longevity Investors Conference","author":"Business Wire","ticker":"NAGE","created":"2026-09-02T12:32:00.145Z","tickers":["NAGE"],"exchange":"NASDAQ","article_body":"Niagen Bioscience to Present at Longevity Investors Conference\n\nNiagen Bioscience, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.niagenbioscience.com%2F&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=Niagen+Bioscience%2C+Inc.&index=1&md5=54ac3dcc4677860f8c64935d818624f4)\n(NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine\ndinucleotide) with a focus on the science of healthy aging, today announces\nthat senior management will participate at the Longevity Investors Conference\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.longevityinvestors.ch%2F&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=Longevity+Investors+Conference&index=2&md5=29d560d7f29c38f3b5547b4ea27ed6ce)\n, taking place from September 14 to 17, 2026, in Gstaad, Switzerland.\n\nNiagen Bioscience CEO, Rob Fried, will participate in the Longevity Goes\nMainstream: The Investment Case for Consumer Health Panel on Wednesday,\nSeptember 16, from 14:50 - 15:30 p.m. CEST. Additionally, Mr. Fried and Niagen\nBioscience Chief Financial Officer & Head of Business Development, Ozan\nPamir, will attend one-on-one meetings with investors in person throughout the\nconference. Attendees will also have the opportunity to sample Tru Niagen(®)\non-site and experience Niagen™ Plus.\n\nThis year’s event will feature institutional investors, family offices,\nfunds, and private investors with the world’s leading longevity scientists\nand key opinion leaders hosting panel discussions to create a forum aimed at\namplifying breakthrough research and scientific advancement shaping the future\nof the longevity space.\n\nIf you would like to schedule a one-on-one meeting with the Niagen Bioscience\nmanagement team during the conference, please contact your respective\nconference representative or email Niagen@KCSA.com (mailto:Niagen@KCSA.com) .\n\nFor additional information on Niagen Bioscience, visit\nwww.niagenbioscience.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.niagenbioscience.com&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=www.niagenbioscience.com&index=3&md5=2d9fcdedf7744202de96e47fd71b0990)\n.\n\nAbout Niagen Bioscience\n\nNiagen Bioscience, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.niagenbioscience.com%2F&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=Niagen+Bioscience%2C+Inc.&index=4&md5=91ef63b35ff133358237c4d430c03bee)\n(NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide\nadenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries,\nNiagen Bioscience(™) is dedicated to advancing healthspan through precision\nscience and innovative NAD+-boosting solutions.\n\nThe Niagen Bioscience team, composed of world-renowned scientists, works with\nindependent investigators from esteemed universities and research institutions\naround the globe to uncover the full potential of NAD+. A vital coenzyme found\nin every cell of the human body, NAD+ declines with age and exposure to\neveryday lifestyle stressors. NAD+ depletion is a key contributor to\nage-related changes in health and vitality.\n\nDistinguished by state-of-the-art laboratories, rigorous scientific and\nquality protocols, and collaborations with leading research institutions\nworldwide, Niagen Bioscience sets the gold standard for research, quality, and\ninnovation. There’s a better way to age.\n\nAt the heart of its clinically tested product portfolio is Niagen(®)\n(patented nicotinamide riboside, or NR), the most efficient, well-researched,\nand high-quality NAD+ booster available. Niagen powers the Company’s\nconsumer supplement, Tru Niagen(®), the number one NAD+ boosting oral\nsupplement in the United States† (available at www.truniagen.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.truniagen.com&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=www.truniagen.com&index=5&md5=a45b8074c93bb2c21c8f7c72385abf48)\n), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and\ninjectable Niagen products (www.niagenplus.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.niagenplus.com&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=www.niagenplus.com&index=6&md5=346991c9ebe4026ac930635a078e26b0)\n). Pharmaceutical-grade Niagen IV and injections are compounded and\ndistributed by U.S. FDA-registered 503B outsourcing facilities and are\navailable exclusively at clinics with a prescription. NAD Pharmaceuticals\nCorp., the Company’s wholly owned subsidiary focused on developing therapies\nfor accelerated aging and rare genetic diseases, is conducting research on\nNB4168, a differentiated small molecule.\n\nNiagen Bioscience’s robust patent portfolio protects NR and other NAD+\nprecursors. Niagen Bioscience maintains a website at www.niagenbioscience.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.niagenbioscience.com&esheet=54597522&newsitemid=20260902223169&lan=en-US&anchor=www.niagenbioscience.com&index=7&md5=58cf5409997dfc1b23998164161facde)\n, where copies of press releases, news, and financial information are\nregularly published.\n\n(†)Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 –\nDec. 2025)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260902223169/en/\n(https://www.businesswire.com/news/home/20260902223169/en/)\n\nNiagen Bioscience Media Contact:\nKendall Knysch, Senior Director of Media Relations & Partnerships\n310.405.5227\nkendall.knysch@niagenbio.com (mailto:kendall.knysch@niagenbio.com)\n\nNiagen Bioscience Investor Relations Contact:\nValter Pinto, Managing Director\nKCSA Strategic Communications\n212.896.1254\nNiagen@kcsa.com (mailto:Niagen@kcsa.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-02T12:32:00.198934332Z","server_sent_at_ms":1788352320198},"received_at":"2026-09-02T12:32:00.413Z","source_url":"https://www.businesswire.com/news/home/20260902223169/en/"},"analysis":{"id":"122828","press_release_id":"133934","analysis_json":{"industry":{"label":"Personal Care Products","sector":"Consumer Staples"},"redFlags":[],"eventType":"other","narrative":"Niagen Bioscience (NASDAQ: NAGE) announced that senior management will participate in the Longevity Investors Conference taking place September 14-17, 2026, in Gstaad, Switzerland.\n\nCEO Rob Fried will join the Longevity Goes Mainstream: The Investment Case for Consumer Health panel on September 16, and Fried and CFO & Head of Business Development Ozan Pamir will hold one-on-one meetings with investors throughout the event.\n\nThe release contains no new financial, clinical, or strategic information; it is a routine IR visibility announcement that also notes attendees can sample Tru Niagen and Niagen Plus on-site.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference-participation notice with no new disclosures -- useful only for IR calendar tracking, suppress from news feed."},"keyFigures":{"customDimensions":{"location":"Gstaad, Switzerland","conference":"Longevity Investors Conference","panelSession":"Longevity Goes Mainstream: The Investment Case for Consumer Health, September 16, 14:50-15:30 CEST","conferenceDates":"September 14-17, 2026"}},"namedEntities":{"people":[{"name":"Rob Fried","role":"CEO"},{"name":"Ozan Pamir","role":"CFO & Head of Business Development"},{"name":"Kendall Knysch","role":"Senior Director of Media Relations & Partnerships"},{"name":"Valter Pinto","role":"Managing Director, KCSA Strategic Communications (investor relations contact)"}],"products":["Tru Niagen","Niagen Plus","Niagen (patented nicotinamide riboside, NR)","NB4168"],"companies":[{"name":"Niagen Bioscience, Inc.","ticker":"NAGE","relationship":"filer"},{"name":"KCSA Strategic Communications","relationship":"investor relations agency"},{"name":"NAD Pharmaceuticals Corp.","relationship":"wholly owned subsidiary"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-relations announcement of conference participation and one-on-one meetings. No new financial results, clinical data, guidance, or strategic disclosures are included."},"tickerRelevance":{"others":[],"primary":"NAGE"},"globalImportance":8,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-ir-conference-announcement","newInformation":"none","householdBrandBoost":0,"retailFavoriteBoost":"minor -- longevity supplement niche has some retail interest"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Niagen Bioscience (NASDAQ: NAGE) announced that senior management will participate in the Longevity Investors Conference taking place September 14-17, 2026, in Gstaad, Switzerland.\n\nCEO Rob Fried will join the Longevity Goes Mainstream: The Investment Case for Consumer Health panel on September 16, and Fried and CFO & Head of Business Development Ozan Pamir will hold one-on-one meetings with investors throughout the event.\n\nThe release contains no new financial, clinical, or strategic information; it is a routine IR visibility announcement that also notes attendees can sample Tru Niagen and Niagen Plus on-site.","key_figures":{"customDimensions":{"location":"Gstaad, Switzerland","conference":"Longevity Investors Conference","panelSession":"Longevity Goes Mainstream: The Investment Case for Consumer Health, September 16, 14:50-15:30 CEST","conferenceDates":"September 14-17, 2026"}},"named_entities":{"people":[{"name":"Rob Fried","role":"CEO"},{"name":"Ozan Pamir","role":"CFO & Head of Business Development"},{"name":"Kendall Knysch","role":"Senior Director of Media Relations & Partnerships"},{"name":"Valter Pinto","role":"Managing Director, KCSA Strategic Communications (investor relations contact)"}],"products":["Tru Niagen","Niagen Plus","Niagen (patented nicotinamide riboside, NR)","NB4168"],"companies":[{"name":"Niagen Bioscience, Inc.","ticker":"NAGE","relationship":"filer"},{"name":"KCSA Strategic Communications","relationship":"investor relations agency"},{"name":"NAD Pharmaceuticals Corp.","relationship":"wholly owned subsidiary"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T15:32:25.156Z","global_importance":8,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-ir-conference-announcement","newInformation":"none","householdBrandBoost":0,"retailFavoriteBoost":"minor -- longevity supplement niche has some retail interest"}},"durationMs":159252,"modelName":"glm-4.7"}}